

Selected Financial Data⁽¹⁾

Merck & Co., Inc. and Subsidiaries

(\$ in millions except per share amounts)

	2005 ⁽²⁾	2004 ⁽³⁾	2003 ⁽⁴⁾	2002	2001	2000
Results for Year:						
Sales	\$22,011.9	\$22,938.6	\$22,485.9	\$21,445.8	\$21,199.0	\$20,009.5
Materials and production costs	5,149.6	4,959.8	4,436.9	4,004.9	3,722.6	3,273.0
Marketing and administrative expenses	7,155.5	7,238.7	6,200.3	5,652.2	5,700.6	5,725.5
Research and development expenses	3,848.0	4,010.2	3,279.9	2,677.2	2,456.4	2,343.8
Restructuring costs	322.2	107.6	194.6	—	—	—
Equity income from affiliates	(1,717.1)	(1,008.2)	(474.2)	(644.7)	(685.9)	(764.9)
Other (income) expense, net	(110.2)	(344.0)	(203.2)	104.5	57.2	69.8
Income from continuing operations before taxes	7,363.9	7,974.5	9,051.6	9,651.7	9,948.1	9,362.3
Taxes on income	2,732.6	2,161.1	2,462.0	2,856.9	2,894.9	2,766.7
Income from continuing operations	4,631.3	5,813.4	6,589.6	6,794.8	7,053.2	6,595.6
Income from discontinued operations, net of taxes	—	—	241.3	354.7	228.6	226.1
Net income	4,631.3	5,813.4	6,830.9	7,149.5	7,281.8	6,821.7
Basic earnings per common share						
Continuing operations	\$2.11	\$2.62	\$2.95	\$3.01	\$3.08	\$2.86
Discontinued operations	—	—	.11	.16	.10	.10
Net income	\$2.11	\$2.62	\$3.05 ⁽⁵⁾	\$3.17	\$3.18	\$2.96
Earnings per common share assuming dilution						
Continuing operations	\$2.10	\$2.61	\$2.92	\$2.98	\$3.04	\$2.80
Discontinued operations	—	—	.11	.16	.10	.10
Net income	\$2.10	\$2.61	\$3.03	\$3.14	\$3.14	\$2.90
Cash dividends declared	3,338.7	3,329.1	3,264.7	3,204.2	3,156.1	2,905.7
Cash dividends paid per common share	\$1.52	\$1.49	\$1.45	\$1.41	\$1.37	\$1.21
Capital expenditures	1,402.7	1,726.1	1,915.9	2,128.1	2,401.8	2,471.0
Depreciation	1,544.2	1,258.7	1,129.6	1,067.5	949.7	803.0
Year-End Position:						
Working capital	\$ 7,745.8	\$ 1,731.1	\$ 1,957.6	\$ 2,011.2	\$ 1,417.4	\$ 3,643.8
Property, plant and equipment (net)	14,398.2	14,713.7	14,169.0	14,195.6	13,103.4	11,482.1
Total assets	44,845.8	42,572.8	40,587.5 ⁽⁶⁾	47,561.2	44,021.2	40,154.9
Long-term debt	5,125.6	4,691.5	5,096.0	4,879.0	4,798.6	3,600.7
Stockholders' equity	17,916.6	17,288.2	15,576.4 ⁽⁶⁾	18,200.5	16,050.1	14,832.4
Financial Ratios:						
Income from continuing operations as a % of sales	21.0%	25.3%	29.3%	31.7%	33.3%	33.0%
Net income as a % of average total assets	10.6%	14.0%	14.9%	15.5%	17.3%	17.9%
Year-End Statistics:						
Average common shares outstanding (millions)	2,197.0	2,219.0	2,236.7	2,257.5	2,288.3	2,306.9
Average common shares						
outstanding assuming dilution (millions)	2,200.4	2,226.4	2,253.1	2,277.0	2,322.3	2,353.2
Number of stockholders of record	198,200	216,100	233,000	246,300	256,200	265,700
Number of employees	61,500	62,600	63,200 ⁽⁶⁾	77,300	78,100	69,300

⁽¹⁾ Prior year amounts have been reclassified to reflect separate line item presentation of Restructuring costs.

⁽²⁾ Amounts for 2005 include the impact of net tax charge primarily associated with the AJCA repatriation, restructuring actions and additional Vioxx legal defense costs.

⁽³⁾ Amounts for 2004 include the impact of the withdrawal of Vioxx and Vioxx legal defense costs.

⁽⁴⁾ Amounts for 2003 include the impact of the implementation of a new distribution program for U.S. wholesalers.

⁽⁵⁾ Amount does not add as a result of rounding.

⁽⁶⁾ Decrease in 2003 primarily reflects the impact of the spin-off of Medco Health.